Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-16
2005-08-16
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S802000, C514S834000, C424S450000, C530S350000, C530S380000, C530S383000
Reexamination Certificate
active
06930087
ABSTRACT:
A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer which carriers substantially no net charge. The protein or polypeptide is capable of externally binding the colloidal particles, or is capable of binding polyethylene glycol, and is not encapsulated in the colloidal particles. A preferred protein is factor VIII, whose half-life is extended and which is protected from serum inhibitor antibodies by injecting it as a component of the composition.
REFERENCES:
patent: 4348384 (1982-09-01), Horikoshi et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5527528 (1996-06-01), Allen et al.
patent: 0 689 428 (1996-01-01), None
patent: WO 80/01456 (1980-07-01), None
patent: WO 91/12021 (1991-08-01), None
patent: WO 94/21235 (1994-09-01), None
Sahli et al., “Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system”, BIOMATERIALS 1997, vol., 18, No. 4, pp. 281-288.
Blume et al., “Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times” BIOCHIMICA ET BIOPHYSICA ACTA, 1449 (1993) 180-184.
Barrowcliffe et al., “Binding to phospholipid protects factor VIII from inactivation by human antibodies” 1983, J. Lab. Clin. Med. 101:34-43.
Kemball-Cook, Interaction of Factor VIII with Phospholipids: Role of Composition and Negative Charge, 1992, Thromb. Res. 67:57-71.
Bloom et al., “Hacmostasis and Thrombosis”, Biochemistry of Prothrombin Activation, pp. 179-180, 1987.
Arakawa et al., “Mechanism of Poly(ethylene glycol) Interaction with Proteins”, BIOCHEMISTRY, vol. 24, No. 24, 1985, pp. 6756-6762.
Lee et al., “Preferential Solvent Interactions between Proteins and Polyethylene Glycols”, Journal of Biological Chemistry, vol. 256, No. 2, Jan. 25, 1981, pp. 625-631.
Bar Liliana
Baru Moshe
Nur Israel
Oliff & Berridg,e PLC
Opperbas Holding B.V.
Schnizer Holly
Weber Jon
LandOfFree
Pharmaceutical composition comprising factor VIII and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition comprising factor VIII and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition comprising factor VIII and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505822